Find the latest news from Novozymes' news archive.
28. February 2013
Reduction of the company’s share capital by cancellation of a part of its holding of treasury B shares. The company’s B share capital is reduced by DKK 10,600,000 from DKK 542,512,800 to DKK 531,912,800.
26. February 2013
Pesky bugs including thrips, mites, whiteflies and vine weevils cause more than $100 million in damage to farmers’ crops every year. Over time, insects can become resistant to pesticides leaving farmers’ valuable crops at risk.
22. February 2013
In reference to company announcement no. 4 of January 31, 2013, the closing conditions for the transaction have been met, and the acquisition of the enzymes business of Iogen Corporation by Novozymes has been completed.
1. February 2013
The Innovation Award is an affirmation of the strong relationship Novozymes has maintained with Henkel over many years. It through close partnerships like these that Novozymes can deliver solutions that positively impact customers’ business.
Election of employee representatives to the Board of Directors of Novozymes AS
31. January 2013
Novozymes acquires Iogen Bio-Products, the industrial enzyme business of Ottawa-based Iogen Corporation for CAD 67.5 million (approximately DKK 370 million) and potential earn-out payments of up to CAD 12.5 million (approximately DKK 70 million).
23. January 2013
In two days, Novozymes has been recognized as being among the top sustainability companies in the world by the Global 100 and by Robeco SAM in The Sustainability Yearbook 2013 .
21. January 2013
New Novozymes President & CEO: Peder Holk Nielsen. Planned leadership transition effective April 1, 2013
He holds a M.Sc. and Ph.D. in Chemical Engineering from the Technical University of Denmark, and a B.Com. in International Business Management from the Copenhagen Business School.
Organic sales growth was 4% (7% DKK, 3% LCY) compared with 2011. EBIT increased by 17%, raising the EBIT margin to 24.4%. Net profit grew by 10%. Strong free cash flow before acquisitions of DKK 1,581 million exceeded the outlook.
11. December 2012
The biobased economy is not science fiction. It is here today. Find out how plants can replace oil-derived products ...
7. December 2012
Comprehensive scientific review of existing studies shows enzyme technology is a promising means of moving towards cleaner industrial production
28. November 2012
Acquisition expands Novozymes’ position in key high-value markets for sustainable bioagriculture solutions.
23. November 2012
A school uniform that continues to look new, after the first week of term, is every parent's dream. Thanks to an enzymatic bioblasting process, UK retailer, Marks & Spencer, has recently turned this into reality.
15. November 2012
Novozymes stands out amongst Danish companies for integrating sustainability in its core activities for the benefit of customers, business and society.
6. November 2012
In reference to company announcement no. 68 of October 29 2012, the closing conditions for the transaction have been met, and the transaction between Novozymes and Beta Renewables has now been closed. Following the transaction, Novozymes’ share of ownership of Beta Renewables is 9.95%.
2. November 2012
Novozymes presents bioinnovations at the AOCS World Conference: enzymes as the perfect match for the unique conditions in China, allowing consumers to save time, money and CO2 when doing their laundry – by hand or by machine.
Novozymes comes in at #5 in CDP Nordic, a global carbon disclosure project in which 655 investors with assets of $78 trillion evaluate companies on their ability to reduce carbon emissions.
30. October 2012
New enzyme allows the biofuel industry to produce more fuel from less corn while improving profits.
29. October 2012
Companies enter into strategic partnership making Novozymes the preferred enzyme supplier for Beta Renewables’ current and future cellulosic biofuel projects.
With the announcement today of the strategic partnership with and acquisition of a share in Beta Renewables (Company announcement No. 68), the aforementioned share buyback program is hereby terminated.
26. October 2012
The partners are entering into an exclusive global marketing and distribution agreement on a unique biofungicide used to combat damaging fungal diseases across a range of crops.
25. October 2012
Sales growth in DKK was 6% (2% LCY, 3% organic) compared with the first 9 months of 2011. EBIT grew by 12%, and the EBIT margin increased to 24.6%. The expectations for full-year 2012 EBIT growth, EBIT margin and net profit growth are maintained, as is the expectation for free cash flow.
| Copyright © 2013 Novozymes. All Rights Reserved.